- Company
- Lilly launches Ebglyss in Korea… sparks competition
- by Son, Hyung Min Jul 3, 2025 06:12am
- The official launch of Lilly's Ebglyss has expanded treatment options for atopic dermatitis patients in Korea. With the arrival of Ebglyss, the number of biological agents available for the treatment of atopic dermatitis in Korea has increased to three. Experts welcomed the emergence of diverse treatment options but emphasized that there i
- Company
- Will twice-yearly Bayer's 'Eylea' become available in KOR?
- by Eo, Yun-Ho Jul 3, 2025 06:12am
- Twice-yearly administration of 'Eylea,' used to treat eye disease, is anticipated to be possible in South Korea. The Ministry of Food and Drug Safety (MFDS) is conducting a review of the expanded indication for the administration of Bayer Korea's high-dose Eylea (aflibercept) 8 mg at intervals of up to 6-months. The approval is expected i
- Company
- Pharma tries to flip the returned out-licensing of new drugs
- by Son, Hyung Min Jul 3, 2025 06:11am
- New drug candidates from Korean pharmaceutical companies, which were previously returned after technology transfer, are now re-entering the clinical stage and proving their potential. Attention is focused on whether these candidates will re-label their past failures and demonstrate technological potential. According to industry sources on Jul
- Company
- SK Bioscience invests billions in the post-pandemic era
- by Chon, Seung-Hyun Jul 3, 2025 06:10am
- SK Bioscience has taken proactive steps to discover new growth engines in preparation for the post-pandemic era. The company has invested KRW 81.5 billion to expand its vaccine plant in Andong and approximately KRW 300 billion for the acquisition of a German CDMO biotech company. The construction of its headquarters, research center, and factory
- Company
- AbbVie Korea launches new glaucoma treatment 'XEN 63'
- by Whang, byung-woo Jul 3, 2025 06:08am
- AbbVie Korea announced on July 1 that it has launched XEN 63, a new option for glaucoma treatment in patients whose intraocular pressure (IOP) is not controlled by previous glaucoma surgery or existing medicines. With the expansion of the XEN Gel Implant portfolio, including XEN 45, patients now have a wider range of personalized treatment
- Company
- Leclaza combination therapy takes over Europe
- by Moon, sung-ho Jul 3, 2025 06:07am
- Leclaza (lazertinib), a new lung cancer drug developed by Yuhan Corporation, has been officially included in the European Society for Medical Oncology (ESMO) guidelines. Reflecting the latest clinical study findings, Leclaza in combination with Rybrevant (amivantamab, Johnson & Johnson) has been included as a first-line option in the guidelin
- Policy
- Pressures to reform Korea's drug pricing system
- by Lee, Tak-Sun Jul 2, 2025 06:10am
- President Trump's signing of the executive order on May 12 to lower prescription drug prices in the United States to the same level as other countries has deepened the concerns of Korea’s authorities as well. This is because the U.S.&160;Pharmaceutical Research and Manufacturers of America and others are demanding that Korea raise drug
- Company
- ‘TNF-α inhibitors, a cornerstone for rheumatoid arthritis'
- by Whang, byung-woo Jul 2, 2025 06:09am
- Rheumatoid arthritis is a chronic autoimmune condition that causes inflammation in the joints, leading to pain and deformity. Its prevalence in Korea is estimated to be approximately 0.5&8211;1% Recently, with the development of new treatments and improved awareness of the disease, early diagnosis rates are on the rise. In fact, over the
- Company
- K-CAB·Entresto awaiting the Supreme Court rulings
- by Kim, Jin-Gu Jul 2, 2025 06:09am
- Patent disputes involving blockbuster drugs, K-CAB (tegoprazan) and Entresto (valsartan/sacubitril), are reaching their final stages. Observations suggest that the Supreme Court's final ruling could come as early as the second half of this year. K-CAB's annual prescription sales amount to KRW 200 billion, while Entresto's are KRW 70 billion.
- Opinion
- [Reporter’s View] Doctors agree Korea’s reimb is too slow
- by Eo, Yun-Ho Jul 2, 2025 06:09am
- Even prescribing physicians believe that the pace of new drug reimbursement listing in Korea is too slow. This is an issue not only for doctors or patients, but obviously for pharmaceutical companies as well. Recently, the Korean Research-based Pharmaceutical Industry Association (KRPIA) released the results of a survey of 100 medical pro
